GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Gross-Profit-to-Asset %

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Gross-Profit-to-Asset % : 25.00% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Biocytogen Pharmaceuticals (Beijing) Co's annualized Gross Profit for the quarter that ended in Jun. 2024 was €78.2 Mil. Biocytogen Pharmaceuticals (Beijing) Co's average Total Assets over the quarter that ended in Jun. 2024 was €313.0 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 25.00%.

Biocytogen Pharmaceuticals (Beijing) Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Gross-Profit-to-Asset % Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
7.18 11.23 15.18 18.74

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial 15.05 17.74 16.64 20.91 25.00

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Gross-Profit-to-Asset % falls into.


Biocytogen Pharmaceuticals (Beijing) Co Gross-Profit-to-Asset % Calculation

Biocytogen Pharmaceuticals (Beijing) Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=64.989/( (379.11+314.572)/ 2 )
=64.989/346.841
=18.74 %

Biocytogen Pharmaceuticals (Beijing) Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=78.24/( (314.572+311.458)/ 2 )
=78.24/313.015
=25.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Biocytogen Pharmaceuticals (Beijing) Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
HKSE:06955 HKSE:02105 HKSE:06855 HKSE:02696 HKSE:02480 HKSE:00775 HKSE:01952 HKSE:02157 HKSE:02171 HKSE:02487 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
02315:Hong Kong
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Website
https://www.biocytogen.com.cn
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines